Bone Abstracts

We and others have recently showed that patients with type 2 diabetes mellitus (T2DM) have a higher risk for fracture, although they have normal or slightly higher bone mineral density (BMD). These findings suggest that bone fragility in T2DM, which is not defined by BMD, may contribute to fracture risk. Hyperglycemia accelerates the formation of advanced glycation end products (AGEs) and causes diabetic complications. AGEs including pentosidine are also known to cause bone fr...

Alendronate is one of the most popular anti-resorptive drugs and widely used to treat osteoporotic patients in the world. In Japan, alendronate oral jelly (ALN-J) as a new formulation was launched in 2013. Dissolution test and bioequivalence study were performed between ALN-J and alendronate oral weekly tablet (ALN-T), and bioequivalence of both drugs was approved. Dosage and administration of ALN-J is the same as ALN-T. Moreover, ALN-J has special features of easy swallowing ...

To assess the associations among diseases causing disability requiring support, including i) musculoskeletal diseases (knee osteoarthritis (KOA), lumbar spondylosis (LS), and osteoporosis (OP)); ii) metabolic risk factors for cardiovascular diseases, including overweight (OW), hypertension (HT), dyslipidaemia (DL), and impaired glucose tolerance (IGT); and iii) mild cognitive impairment (MCI).Among 1690 participants (596 men and 1094 women) at the baseli...

In type 2 diabetes mellitus (T2DM) patients, an increased fracture risk is observed, although the bone mineral density is even higher than in non-diabetic patients, which raises the question of the quality of the organic and inorganic matrix in bone1,2. T2DM is also known to favor inflammation of the gingiva and paradontosis in general. However, little is known about the mineral nano-architecture in the mandible and about the possible influence of diabetes. Using sy...

Introduction: Minodronate, a new-generation bisphosphonate (BP), is the first BP available as a once-monthly oral regimen in Japan. Aside from being a highly potent inhibitor of bone resorption, minodronate has been shown to possess antagonistic action against the P2X2/3 receptor, which has an important role in nociceptive transmission. The purpose of this study was to investigate the analgesic effects of once-monthly oral minodronate (MIN50 mg) on low back pain (LBP) associat...

Introduction: Minodronate, a highly potent, new-generation bisphosphonate (BP), is the first BP available as a once-monthly oral regimen in Japan. The aim of the present study was to investigate the effects of once-monthly oral minodronate on bone turnover markers (BTM) and bone mineral density (BMD) in osteoporotic patients previously using daily or weekly BPs in real clinical practice.Methods: We conducted a prospective multicenter study involving 11 i...

Introduction: Bisphosphonates (BPs) are currently the mainstay of treatment in osteoporosis; however, the complex dosing regimens might interfere with long-term adherence, which provided the rationale to develop BPs with less-frequent dosing schedules. Minodronate (MIN 50 mg), a highly potent new-generation BP, is the first BP available as a once-monthly oral regimen in Japan. The aim of the present study was to investigate patient preference for, and adherence to, MIN 50 mg i...

Purposes: The trabecular bone score (TBS) is an indicator of cancellous bone microstructure obtained from image analysis with lumbar spine dual-energy X-ray absorptiometry (DXA) scans. A decrease in TBS is considered to be a risk factor for vertebral fracture that is independent of BMD. At the same time, it has been reported that, BMD was higher and TBS was lower in women with type 2 diabetes mellitus (DM), and a decreasing TBS is risk factor for fracture. However, the relatio...

Introduction: Recessive osteogenesis imperfecta (OI) is caused by mutations in genes encoding proteins involved in post-translational interactions with type I collagen. Types VII–IX OI involve defects in the collagen prolyl 3-hydroxylation complex, which modifies α1(I)Pro986. PPIB encodes CyPB, a complex component with PPIase activity and the major isomerase facilitating collagen folding. We investigated the role of CyPB in collagen post-translational modifications a...